Repligen Financials
| RGEN Stock | USD 163.63 0.29 0.18% |
Repligen Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.33 | 0.31 |
|
| |||||
| Current Ratio | 9.47 | 9.67 |
|
|
The essential information of the day-to-day investment outlook for Repligen includes many different criteria found on its balance sheet. An individual investor should monitor Repligen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Repligen.
Net Income |
|
Repligen | Select Account or Indicator | Build AI portfolio with Repligen Stock |
Repligen Earnings Geography
Repligen Stock Summary
Repligen competes with Avantor, Masimo, Baxter International, AptarGroup, and Bio Rad. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US7599161095 |
| Business Address | Building 1, Waltham, |
| Sector | Life Sciences Tools & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.repligen.com |
| Phone | 781 250 0111 |
| Currency | USD - US Dollar |
Repligen Key Financial Ratios
| Return On Equity | 9.0E-4 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.07 % | ||||
| Price To Sales | 12.73 X | ||||
| Revenue | 634.44 M |
Repligen Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 2.4B | 2.5B | 2.8B | 2.8B | 3.3B | 3.4B | |
| Other Current Liab | 55.8M | 63.3M | 46.4M | 66.3M | 76.3M | 80.1M | |
| Net Debt | (237.8M) | (100.5M) | (39.5M) | (71.1M) | (64.0M) | (67.2M) | |
| Retained Earnings | 194.1M | 397.3M | 438.8M | 407.4M | 468.5M | 491.9M | |
| Cash | 603.8M | 523.5M | 751.3M | 757.4M | 871.0M | 914.5M | |
| Net Receivables | 117.4M | 116.2M | 124.2M | 134.1M | 154.2M | 161.9M | |
| Inventory | 184.5M | 238.3M | 202.3M | 143.0M | 164.4M | 172.6M | |
| Other Current Assets | 25.9M | 19.8M | 33.2M | 31.6M | 36.3M | 38.2M | |
| Total Liab | 608.3M | 620.9M | 853.2M | 856.9M | 985.5M | 1.0B | |
| Total Current Assets | 931.7M | 998.1M | 1.1B | 1.1B | 1.2B | 1.3B | |
| Accounts Payable | 36.2M | 27.6M | 19.6M | 32.1M | 37.0M | 38.8M | |
| Short Term Debt | 263.6M | 291.6M | 75.1M | 15.1M | 17.4M | 16.5M | |
| Intangible Assets | 337.3M | 360.6M | 400.5M | 397.9M | 457.6M | 480.5M | |
| Other Assets | 28.2M | 2.5M | 1.7M | 282.1M | 253.9M | 266.6M | |
| Common Stock | 553K | 556K | 558K | 561K | 645.2K | 408.0K | |
| Other Liab | 32.3M | 28.4M | 130.5M | 78.4M | 90.1M | 94.6M | |
| Good Will | 860.4M | 855.5M | 987.1M | 1.0B | 1.2B | 1.2B | |
| Net Tangible Assets | 378.8M | 623.7M | 552.4M | 701.5M | 806.7M | 847.1M | |
| Capital Surpluse | 1.1B | 1.5B | 1.6B | 1.5B | 1.8B | 1.9B |
Repligen Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Interest Expense | 12.7M | 3.0M | 10.0M | 22.6M | 20.3M | 21.3M | |
| Total Revenue | 670.5M | 801.5M | 638.8M | 634.4M | 729.6M | 766.0M | |
| Gross Profit | 391.3M | 455.7M | 284.2M | 274.6M | 315.8M | 532.0M | |
| Operating Income | 167.2M | 224.7M | 54.6M | (35.1M) | (40.4M) | (38.4M) | |
| Ebit | 164.8M | 220.3M | 56.2M | (6.3M) | (7.2M) | (7.6M) | |
| Ebitda | 203.3M | 277.3M | 124.3M | 80.3M | 92.3M | 96.9M | |
| Cost Of Revenue | 279.3M | 345.8M | 354.5M | 359.8M | 413.8M | 234.1M | |
| Income Before Tax | 153.5M | 219.1M | 64.1M | (27.0M) | (31.1M) | (32.6M) | |
| Net Income | 128.3M | 186.0M | 41.6M | (25.5M) | (23.0M) | (24.1M) | |
| Income Tax Expense | 25.3M | 33.2M | 22.6M | (1.5M) | (1.7M) | (1.7M) | |
| Research Development | 34.3M | 43.9M | 42.7M | 43.2M | 49.7M | 47.2M | |
| Tax Provision | 25.3M | 33.2M | 10.1M | (1.5M) | (1.7M) | (1.7M) | |
| Net Interest Income | (12.7M) | (3.0M) | (2.9M) | (22.6M) | (20.3M) | (19.3M) |
Repligen Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change To Inventory | (89.8M) | (57.2M) | 41.0M | 56.9M | 51.2M | 53.8M | |
| Change In Cash | (113.5M) | (80.4M) | 227.9M | 6.0M | 6.9M | 6.6M | |
| Free Cash Flow | 47.7M | 38.7M | 74.9M | 142.5M | 163.9M | 172.1M | |
| Depreciation | 38.4M | 57.0M | 68.1M | 86.6M | 99.5M | 104.5M | |
| Other Non Cash Items | 20.4M | (27.0M) | (15.0M) | 5.4M | 6.2M | 6.5M | |
| Capital Expenditures | 71.3M | 133.3M | 39.0M | 32.9M | 37.8M | 30.5M | |
| Net Income | 128.3M | 186.0M | 41.6M | (25.5M) | (29.3M) | (30.8M) | |
| End Period Cash Flow | 603.8M | 523.5M | 751.3M | 757.4M | 871.0M | 914.5M | |
| Investments | (221.2M) | (100M) | (74.7M) | (86.4M) | (77.7M) | (81.6M) | |
| Change Receivables | (7.8M) | (20.9M) | (46.5M) | (3.6M) | (3.2M) | (3.4M) | |
| Change To Netincome | 18.5M | 13.3M | 34.9M | 25.9M | 29.7M | 31.2M |
Repligen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Repligen's current stock value. Our valuation model uses many indicators to compare Repligen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repligen competition to find correlations between indicators driving Repligen's intrinsic value. More Info.Repligen is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about 14.44 of Return On Asset per Return On Equity. At this time, Repligen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Repligen's earnings, one of the primary drivers of an investment's value.Repligen's Earnings Breakdown by Geography
Most indicators from Repligen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repligen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.At this time, Repligen's Selling General Administrative is very stable compared to the past year. As of the 29th of January 2026, Enterprise Value Over EBITDA is likely to grow to 120.07, though Tax Provision is likely to grow to (1.7 M).
| 2023 | 2024 | 2025 | 2026 (projected) | Gross Profit | 284.2M | 274.6M | 315.8M | 532.0M | Total Revenue | 638.8M | 634.4M | 729.6M | 766.0M |
Repligen fundamental ratios Correlations
Click cells to compare fundamentals
Repligen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Repligen fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 2.4B | 2.5B | 2.8B | 2.8B | 3.3B | 3.4B | |
| Other Current Liab | 55.8M | 63.3M | 46.4M | 66.3M | 76.3M | 80.1M | |
| Net Debt | (237.8M) | (100.5M) | (39.5M) | (71.1M) | (64.0M) | (67.2M) | |
| Retained Earnings | 194.1M | 397.3M | 438.8M | 407.4M | 468.5M | 491.9M | |
| Cash | 603.8M | 523.5M | 751.3M | 757.4M | 871.0M | 914.5M | |
| Net Receivables | 117.4M | 116.2M | 124.2M | 134.1M | 154.2M | 161.9M | |
| Inventory | 184.5M | 238.3M | 202.3M | 143.0M | 164.4M | 172.6M | |
| Other Current Assets | 25.9M | 19.8M | 33.2M | 31.6M | 36.3M | 38.2M | |
| Total Liab | 608.3M | 620.9M | 853.2M | 856.9M | 985.5M | 1.0B | |
| Total Current Assets | 931.7M | 998.1M | 1.1B | 1.1B | 1.2B | 1.3B | |
| Accounts Payable | 36.2M | 27.6M | 19.6M | 32.1M | 37.0M | 38.8M | |
| Short Term Debt | 263.6M | 291.6M | 75.1M | 15.1M | 17.4M | 16.5M | |
| Intangible Assets | 337.3M | 360.6M | 400.5M | 397.9M | 457.6M | 480.5M | |
| Other Assets | 28.2M | 2.5M | 1.7M | 282.1M | 253.9M | 266.6M | |
| Common Stock | 553K | 556K | 558K | 561K | 645.2K | 408.0K | |
| Other Liab | 32.3M | 28.4M | 130.5M | 78.4M | 90.1M | 94.6M | |
| Good Will | 860.4M | 855.5M | 987.1M | 1.0B | 1.2B | 1.2B | |
| Net Tangible Assets | 378.8M | 623.7M | 552.4M | 701.5M | 806.7M | 847.1M | |
| Capital Surpluse | 1.1B | 1.5B | 1.6B | 1.5B | 1.8B | 1.9B |
Today, most investors in Repligen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Repligen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Repligen growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Repligen January 29, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Repligen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Repligen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Repligen based on widely used predictive technical indicators. In general, we focus on analyzing Repligen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Repligen's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.16 | |||
| Information Ratio | 0.004 | |||
| Maximum Drawdown | 10.86 | |||
| Value At Risk | (3.16) | |||
| Potential Upside | 4.07 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Life Sciences Tools & Services sector continue expanding? Could Repligen diversify its offerings? Factors like these will boost the valuation of Repligen. Anticipated expansion of Repligen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Repligen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.6 | Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth 0.219 | Return On Assets |
Investors evaluate Repligen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Repligen's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Repligen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Repligen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Repligen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Repligen's market price signifies the transaction level at which participants voluntarily complete trades.